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Abstract 
Metabotropic glutamate (mGlu) receptors are expressed in key regions of the cortex and the 
thalamus and are known to regulate spike and wave discharges (SWDs), the electroclinical 
hallmarks of absence seizures. Recent preclinical studies have highlighted the therapeutic 
potential of selective group I and III mGlu receptor subtype allosteric modulators, which can 
suppress pathological SWDs. Of particular interest are positive allosteric modulators (PAMs) 
for mGlu5 receptors, as they currently show the most promise as novel anti-absence epilepsy 
drugs. The rational design of novel selective positive and negative allosteric mGlu modulators, 
especially for the mGlu5 receptor, has been made possible following the recent 
crystallographic structure determination of group I mGlu receptors. Our current knowledge of 
the role of different mGlu receptor subtypes in absence epilepsy is outlined in this article. 
 
 
Highlights:  
- mGlu receptors are located within the cortico-thalamo-cortical system, which generates 
spike-wave discharges typical of absence epilepsies. 
- mGlu receptors of all three subgroups are involved in the control of SWDs, although 
selective PAMs and NAMs are not available for all receptor subtypes.  
- The pharmacological profile of a mGlu5 receptor PAM has a good preclinical anti-
absence profile. 
- The mGlu7 receptor seems to be an attractive target for putative anti-absence drugs.   
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Introduction 
Absence epilepsy is non-convulsive and is characterized by a sudden decrease in 
responsiveness, accompanied by staring and the simultaneous appearance of highly 
stereotypical bilateral symmetrical network activity in the form of spike-and-wave discharges 
(SWDs) in the EEG. The main anatomical structure where these SWDs are generated is the 
extensive cortico-thalamo-cortical network which includes the reticular thalamic nucleus 
(nRT) [1*,2, 3*,4]. The frontal cortex has been identified as the major initiation site for SWDs 
in some patients [5], although other cortical locations including the temporal, occipital and 
parietal lobe can also be initiation sites [6]. In a widely used and validated genetic absence 
animal model, the WAG/Rij strain of rat, the peri-oral region of the somatosensory cortex 
(S1po) has been identified as the SWD initiation site [5]. These WAG/Rij rats are an inbred 
strain that shows an age-dependent increase in the probability of developing spontaneous 
SWDs. Following their development, SWDs increase in both frequency and mean duration. 
SWDs occur mainly during passive wakefulness, in an otherwise motionless animal, not during 
deep slow wave sleep. During SWDs, animals do not make overt behavioural responses to 
obtain food pellets, as they would do normally suggesting that responsiveness is reduced. 
Many classical and newer antiepileptic drugs have been tested in this and in a similar absence 
model, the GAERS (Genetic absence epilepsy rats from Strasbourg) .  Based on the outcomes 
of such experiments, it has been concluded that these animal models provide a good prediction 
of the efficacy of drugs and the possible off-target effects that will be observed in humans with 
absence seizures [3].   
 
The glutamatergic and GABAergic systems are involved in controlling excitation and 
inhibition respectively, in the cortex and thalamus. Aside from the highly excitable site in the 
cortex that initiates SWDs in WAG/Rij rats and in GAERS, increased thalamic tonic 
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GABAergic inhibition has also been demonstrated in some genetic absence epilepsy models 
[7*, 8*]. The fact that metabotropic glutamate (mGlu) receptors are expressed in different 
regional circuit cell types within cortico-thalamo-cortical networks, and that they modulate 
synaptic transmission [9*,10, 11] (see also Figure 1), suggest a potential role for mGlu 
receptors in regulating SWDs.  
The mGlu receptors are classified into three main groups (I, II and III), and pre-clinical studies 
to date have shown that ligands for the different receptor subtypes in each group have anti-
absence properties [12*, 13-15, 16*, 17-19].  
 Furthermore, interest in identifying new mGlu receptor ligands with anti-absence properties 
has been encouraged by the discovery of distinct allosteric binding sites in the crystallographic 
structure of transmembrane domains in group I mGlu receptors (mGlu1 and mGlu5 receptors), 
permitting a rational design of specific compounds [20*,21*]. Here, we focus on the role of 
mGlu receptors and their allosteric modulators as studied in the WAG/Rij rat model of absence 
epilepsy [3]. 
  
Localisation and modulation of mGlu receptors in the cortico-thalamo-
cortical circuitry 
The classification of mGlu receptors into groups is based on their pharmacological properties 
and amino acid sequence homology profile [12,22,23]. These receptors are coupled to 
different G proteins and they modulate slow postsynaptic neuronal responses, either through 
the presynaptic or postsynaptic machinery or through modulating astrocytes function [9-12, 
24] (see also Figure 1).  
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Group, I mGlu receptors 
mGlu1 and mGlu5 receptor subtypes are members of group I and they are coupled to Gq/ G11 
proteins, which upon activation trigger polyphosphoinositide hydrolysis leading to the 
production of inositol-1,4,5-trisphosphate and diacylglycerol.  These receptors are also able to 
regulate the activity of different types of Ca2+ and K+ channels [22,25,26] (see also Table 1). 
Data from molecular studies show that they are localized on postsynaptic dendrites of thalamic 
neurons and on GABAergic interneurons in the cortex [27-30]. Glial cells expressing mGlu5 
receptors may also modulate synapses within the thalamus, particularly on inputs to the 
somatosensory ventrobasal (VB) thalamus [31] (see also Figure 1). 
Group I mGlu receptors are the most extensively studied group in the WAG/Rij rat model [11]: 
the expression of both receptor subtypes (mGlu1 and mGlu5) have been shown to be reduced 
in the thalamus as compared to non-epileptic ACI control rats [13, 14]. Similar results have 
been observed for mGlu1 expression in the laterodorsal thalamus in the same model [32]. 
Interestingly, mGlu5 receptor expression was up-regulated in the motor cortex and in the S1po 
region, again in comparison with age-matched ACI rats, without any change in mGlu5 receptor 
function. Overall, both receptors show reduced expression and activity in the cortico-thalamo-
cortical network in the WAG/Rij rat [13, 14, 32].  
Electroencephalographic (EEG) studies carried out following systemic treatment with the 
specific mGlu1 receptor positive allosteric modulator (PAM) RO0711401 showed a long-
lasting (6 hours) dose-related reduction in frequency and duration of SWDs (the latter only 
occurring only after the highest dose). As expected, treatment with the mGlu1 negative 
allosteric modulator (NAM) JNJ16259685 increased the incidence of SWDs [13], (see also 
Table 1). The mGlu5 receptor PAM VU0360172 reduced the number of SWDs in a dose-
dependent manner, without any behavioural changes, such as an increase or decrease in 
locomotor activity in the home cage. The reduction of SWDs was antagonized by the mGlu5 
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receptor NAM, MTEP.  MTEP itself was without any effect on SWDs [13] (see also Table 1). 
The lack of behavioural effects is important since clinically useful anti-epileptic drugs should 
lack sedative or hypnotic effects. Intriguingly, MPEP significantly reduced the occurrence of 
SWDs in the lethargic mouse (lh/lh) model [33-35], a different genetic absence model, in which 
animals show an ataxic gait in addition to SWDs. Moreover, the mGlu1 receptor orthosteric 
antagonists AIDA and LY367385 reduced SWDs in the same model [34]. These results are in 
contrast with those obtained in WAG/Rij rats. It is not clear whether these differences could be 
due to the different species used or to differences in ligand-site activity on receptor subtypes. 
Considering that absence epilepsy is a chronic disease requiring long-term treatment, the 
effects of chronic administration of both selective group I receptor subtype PAMs were tested 
to see whether tolerance developed to the suppressing effects on SWDs. WAG/Rij rats were 
treated with comparable doses of each compound (RO0711401 and VU0360172) for 10 days 
twice daily. The rats developed complete tolerance to RO0711401 after 2 days, while 
VU0360172 maintained its anti-SWD effects throughout this period and even after 48 hours 
from ceasing treatment [15] (see also Table 1). The mechanism for this tolerance remains 
unclear, but it limits the clinical usefulness of RO0711401.  
Further studies have been carried out to determine which regions within the cortex or the 
thalamus were responsible for the effects observed following systemic injection of the mGlu1 
or mGlu5 receptor PAMs. When either RO0711401 or VU0360172 were individually 
administered locally into the cortex or the thalamus, both proportionally reduced SWDs. 
However, when introduced into the thalamus, VU0360172 had a more pronounced efficacy 
than RO0711401 [16].   
How do these PAMs reduce SWDs? Both mGlu1 and mGlu5 receptors are coupled to second 
messenger effectors, including PLC-beta 4; these may negatively regulate T-type calcium 
channels in the cortex and thalamus, reducing SWDs [36-39]. Of note, mutation of PLC-beta 
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4 is known to influence pathological cortico-thalamo-cortical rhythms associated with T-type 
channels [40]. 
As previously stated, in physiological conditions glutamate and GABA are in a critical balance 
within the cortico-thalamo-cortical network [1,12,16]. Coenen and collaborators have shown 
that systemic injection of tiagabine a GABA re-uptake inhibitor with high affinity at the GABA 
transporter (GAT-1) – upset the balance, leading to increased SWD frequency and duration in 
WAG/Rij rats [41]. When tiagabine was administered intra-cortically at the focal region, it 
reduced the number of SWDs, similarly to the effect produced by local infusion of VU0360172 
[16]. Intra-cortical injection of VU0360172 in combination with tiagabine produced a slight 
prolongation of the SWD suppressive effect, suggesting that the modes of action of 
VU0360172 and tiagabine may be similar [16]. Opposite results were obtained when tiagabine 
was infused in the thalamus: it enhanced SWDs, most likely by increasing GABA levels 
perisynaptically at thalamic relay cells. Interestingly, VU0360172 lost its anti-absence action 
when it was infused in the thalamus in combination with tiagabine [16].   
Regarding VU0360172, the group I mGlu5 receptor PAM, it produced neither tolerance nor 
overt effects on behaviour but had good efficacy in the cortex and thalamus. Interestingly, one 
of the drugs of choice in the treatment of absence epilepsy, ethosuximide, is also highly 
effective in the cortex, but less so in the thalamus [42]. This demonstrates the importance of 
targeting mGlu5 receptors for the development of novel anti-absence drugs.  
 
Group II mGlu receptors 
Group II (mGlu2 and mGlu3) receptors are coupled to Gi/Go proteins, which inhibit the 
activity of adenyl cyclase and voltage-sensitive Ca2+ channels (VSCCs) [22,26]. Molecular 
analysis shows that mGlu3 receptors have a higher expression on GABAergic terminals of the 
nRT than at glutamatergic synapses. These receptors are also present on axons of cortical layer 
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VI [4]. mGlu3 receptors are expressed by glial cells, and mGlu2 receptor activity has been 
identified in astrocytes in the ventrobasal thalamic nuclei [9,28,43] (see also Figure 1). 
In symptomatic WAG/Rij rats, mGlu2/3 receptor expression in the S1po area is altered as 
compared with age-matched controls [17]. Only a few pharmacological studies have been 
carried out with orthosteric ligands for these receptors, one in WAG/Rij rats [17] and one in 
1h/1h mice [45]. In WAG/Rij rats, blockade of the mGlu2/3 receptor with the antagonist 
LY341495 reduced the occurrence of SWDs in a dose-dependent manner, while activation of 
these receptors had opposite effects [17]. Intriguingly, activation of the mGlu2/3 receptor in 
1h/1h mice decreased SWDs activity [45]. It is not known whether these contrasting results are 
due to (mGlu2 or mGlu3) receptor/ligand selectivity, specificity or model/species differences. 
The development of novel specific ligands for mGlu2 and mGlu3 receptors combined with 
genetic manipulation of these receptors might be relevant to unravelling the specific role of 
each subtype.  
 
Group III mGlu receptors 
 
Group III comprises mGlu4, mGlu6, mGlu7 and mGlu8 receptors, which are also coupled to 
Gi/Go proteins, similar to group II receptors. All except mGlu6 are expressed in the cortico-
thalamo-cortical network. mGlu4 receptors are found on glutamatergic terminals in the nRT 
and in the VB, while mGlu7 and mGlu8 are present also on nRT neurons [9, 18, 46-50]. 
Group III mGlu receptors seem to be important in the mechanisms underlying the initiation of 
absence seizures. Different studies link the human mGlu4 receptor gene to genetic/idiopathic 
generalised epilepsies [51-53]. mGlu4 receptor expression is increased in the nRT of 
symptomatic WAG/Rij rats as compared with asymptomatic control rats; pharmacological 
enhancement of the activation of this receptor with the PAM PHCCC increased SWDs [7]. 
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The other group III receptors (namely, mGlu7 and mGlu8) are implicated in the modulation of 
neuronal plasticity, learning, and memory [54,55], and are also involved in seizures and 
epilepsy [56]. mGlu7 knockout mice show increased susceptibility to chemically induced 
seizures [54]. The lack of specific subtype ligands for group III mGlu receptors has limited the 
studies of their individual roles in absence seizures.  
The mGlu7 receptor has a very low affinity for glutamate, and this allows selective recruitment 
of the receptor during high levels of synaptic activity [57]. Conversely, prolonged agonist 
activation of the mGlu7 receptor can also activate a phospholipase C–mediated signalling 
pathway that enhances glutamate release [58].  
Nevertheless, knockout mice in which PDZ-interaction with protein-interaction-C-kinase-
1(PICK-1) signalling decoupled from the C-terminus of the mGlu7 receptor develop 
spontaneous absence-like epilepsy [56]. In addition, a study by Kyuyong and Huguenard has 
demonstrated that mGlu7 receptors are functionally present as autoreceptors on inhibitory 
synapses between nRT and thalamocortical neurons [18] (see also Table 1). 
A recent study demonstrated that mGlu7 receptors are found on synapses projecting onto the 
nRT, and from the nRT onto the VB [19] (see also Figure 1). Blockade of mGlu7 receptor 
activity with the specific mGlu7 receptor NAM ADX71743 induced a lethargic condition 
similar to absence seizures with spindle and/or SWDs. The authors showed that the mGlu7 
receptor regulates tonic modulation, particularly between GABAergic and glutamatergic 
synapses within the cortico-thalamo-cortical network [19].  
In terms of the group III receptors, the properties and location of the mGlu7 receptor make it 
an attractive target in that mGlu7 receptor ligands might be beneficial for the development of 
anti-absence epilepsy drugs.  
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Conclusion 
Targeting subtype-selective metabotropic glutamate receptor is a potentially novel method for 
treating absence seizures given that many of these receptors are expressed in the thalamo-
cortico-thalamic circuit and studies with agents that modulate receptor activity show promise 
in reducing SWD occurrence in animal models. The challenge will be to provide an alternative 
therapy to current medication for the ~40% of absence epilepsy patients who are resistant to 
current drugs [59].  Hypothetically, mGlu PAMs could be developed for sufferers of absence 
seizures refractory to conventional medications. Indeed, ligands for mGlu receptors have been 
under phase I and II clinical investigation for the treatment of CNS disorders [26,60*].  As an 
ultimate goal, the further design of subtype mGlu receptor PAMs with biased allosteric 
modulatory properties is relevant to delivering in vivo efficacy and the elimination of adverse 
effects. 
We propose that designing mGlu receptor ligands with a modulatory effect on voltage-gated 
channels (primarily Cav3.1, the major T-channel in TC neurons) affecting neuronal electrical 
properties during seizures would lead to effective anti-absence therapy with reduced side 
effects associated with non-specific anti-absence medication, such as ethosuximide, which acts 
on Na+ channels as well as T-channels [61,62].  
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Figure and table legends 
Figure_1  
Diagram showing synaptic localization of mGlu receptor subtypes in the modulation of absence 
seizures. In red, dendritic spine from the pyramidal cell (e.g. layer IV), cortico-thalamic (CT) 
glutamatergic projection into the ventrobasal thalamus with collateral onto the reticular 
thalamic nucleus (nRT). Glutamatergic thalamic relay neuron (TC) sends projection (in orange) 
to the deep layers of the cortex (e.g. layer VI) and collateral onto the nRT. GABAergic nRT 
neuron in green, sending projection to the VB and collateral back onto the nRT. The synapses 
are mostly surrounded by astrocytic processes (in purple) expressing distinct mGlu receptor 
subtypes (principally mGlu3 and mGlu5) as indicated by the different colours. The sensory 
afferents at the thalamus are depicted as a large red arrow. mGlu1 and mGlu5 receptors (also 
present on astrocytes) are located perisynaptically at excitatory synapses. Group II receptors 
(mGlu2 and 3) are present in both cortical and thalamic synaptic terminals. mGlu3 receptors 
are expressed in astrocytes, and the activity of mGlu2 has recently been identified on astrocytes 
by a combination of electrophysiological and pharmacological methods. Subtypes of mGlu4, 
7 and 8 are usually localized presynaptically at active regions. 
 
 
Table_1 
A summary of mGlu receptor subtypes, transduction mechanisms and site of action of specific 
subtype receptor ligands and their effect on models of absence epilepsy.  
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• Group I mGlu receptors are predominantly expressed 
post-synaptically and mGlu5 are also on astrocytes
• Group II mGlu receptors are both 
expressed pre and post-synaptically. 
mGlu3 are on astrocytes and recently 
mGlu2 astrocytic activity has been 
identified in  the thalamus 
• Group III mGlu receptors are predominantly 
expressed presynaptically
• Associated with Gq/11 class G proteins
• PLC stimulation
• Stimulation of adenylyl cyclase
• MAP kinase phosphorylation
• Associated with Gi/o class G proteins
• Inhibition of adenylyl cyclase
• Activation of K+ channels
• Inhibition of Ca2+ channels
• Associated with Gi/o class G proteins
• Inhibition of adenylyl cyclase
• Activation of K+ channels
• Inhibition of Ca2+ channels
• RO0711401 reduces SWDs (WAG/Rij rats)  and 
JNJ16259685 increases SWDs (WAG/Rij rats) [21]
• Orthosteric antagonists LY367385 and AIDA reduces 
SWDs in Ih/Ih mice [31,32, 33]
• VU0360172 reduces SWDs in WAG/Rij rats: MTEP 
antagonizes the effect of VU0360172 in  WAG/Rij rats 
[22].
• MPEP mGlu5 NAM with an mGlu4 NAM component 
reduces SWDs in Ih/Ih mice [31] 
• Development of tolerance: VU0360172 (NON after 10 
days), while RO0711401 did develop after 2 days [24]
• Local infusion of  either RO0711401 or VU0360172 
suppressed SWDs independently both in the cortex and 
thalamus  [13]
• LY341495 an orthosteric antagonist 
reduces SWDs in WAG/Rij rats [15]
• LY379268 an orthosteric agonist increases 
SWDs in WAG/Rij rats [15]. LY341495 and 
LY379268 both reduces SWDs in Ih/Ih
mice [41]
• PHCCC enhances SWDs in WAG/Rij rats [6]
• ADX71743 produces lethargic effects similar 
to SWDs in WT mice [44].Decoupling if 
PICK1 from mGlu7 causes SWDs [51]
OrthoAgo = Orthosteric agonist
OrthoAnt =	Orthosteric antagonist
PAM	=	positive	allosteric	modulator
NAM	=	negative allosteric	modulator
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